Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Axitinib plus Sandostatin LAR versus placebo plus Sandostatin LAR in progressive advanced non-pancreatic neuroendocrine carcinoma
2011-001550-29Phase 2Completed
- Sponsor
- Spanish Group of Neuroendocrine Tumors
- Start
- Jan 2012
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in neuroendocrine carcinoma (NEC) and Carcinoid Tumor (CT) comparing Axitinib + Sandostatin LAR with Placebo + Sandostatin LAR (2 arms). Primary endpoint: Progression-free survival. Started Jan 2012; status: completed.
02
Drugs
axitiniboctreotide
03
Conditions
neuroendocrine carcinoma (NEC)Carcinoid Tumor (CT)
Beyond the preview
Go deeper on 2011-001550-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-001550-29.